PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity
Authors:
- 24 February 2014
- journal article
- research article
- Published by Wiley in Cell Biochemistry and Function
- Vol. 32 (4) , 368-377
Abstract
Drugs used in the treatment of type 2 diabetes and cardiovascular disease, specifically peroxisome proliferator‐activated receptor (PPAR) agonists, have been reported to affect bone cell function and fracture risk. In this study, we assessed the direct effects of PPAR‐γ agonists (rosiglitazone and troglitazone), used in the treatment of diabetes, and a PPAR‐α agonist (fenofibrate), used to treat hyperlipidaemia, on the function of primary osteoblasts and osteoclasts. Formation of ‘trabecular’ bone structures by rat calvarial osteoblasts was reduced by up to 85% in cultures treated with rosiglitazone and by 45% in troglitazone‐treated or fenofibrate‐treated cultures; at the same time, lipid droplet formation was increased by 40–70%. The expression of key osteogenic markers was similarly downregulated in cultures treated with PPAR agonists, whereas adipogenesis markers were upregulated. Formation of osteoclasts in cultures derived from mouse marrow diminished with fenofibrate treatment, whereas both glitazones reduced resorptive activity without affecting osteoclast number. Metformin, although not a PPAR agonist, is also commonly used in the treatment of type 2 diabetes. Here, metformin was found to have no effect on bone cell function. Taken together, these data suggest that PPAR‐γ agonists may enhance bone loss via increased adipogenesis at the expense of osteoblast formation. In contrast, PPAR‐α agonists may prevent bone loss. Given that the prevalence of diabetes and cardiovascular disease is expected to rise significantly, greater attention may need to be paid to the effects of PPAR agonists on bone homeostasis. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
This publication has 52 references indexed in Scilit:
- Recent UK trends in the unequal burden of coronary heart diseaseHeart, 2012
- Forming functional fat: a growing understanding of adipocyte differentiationNature Reviews Molecular Cell Biology, 2011
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Forecasting the Future of Cardiovascular Disease in the United StatesCirculation, 2011
- Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- Global estimates of the prevalence of diabetes for 2010 and 2030Diabetes Research and Clinical Practice, 2010
- A Cohort Study of Thiazolidinediones and Fractures in Older Adults with DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Rosiglitazone-Associated Fractures in Type 2 DiabetesDiabetes Care, 2008
- Use of Thiazolidinediones and Fracture RiskArchives of internal medicine (1960), 2008
- ThiazolidinedionesNew England Journal of Medicine, 2004